

## Special Issue

# Updates on the Genetics of Myeloid Malignancies

### Message from the Guest Editor

Myeloid malignancies are clonal hematopoietic disorders characterized by the presence of mutations in hematopoietic progenitors. The application of modern genome sequencing has provided clues to identify novel mutated gene pathways and their roles in disease pathogenesis. Computer science has created the possibility to build algorithms and bioinformatics tools to incorporate a variety of genomic information possibly leading to improvement in the selection of therapeutics in the near future. This special issue is open to original research articles and reviews on the scope of genetics and genomics of myeloid malignancies. Submissions on artificial intelligence and novel computational methods on genetics features of myeloid malignancies is highly encouraged.

---

### Guest Editor

Dr. Valeria Visconte

Department of Translational Hematology and Oncology Research,  
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA

---

### Deadline for manuscript submissions

closed (25 November 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/148697](https://mdpi.com/si/148697)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)